Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial

Purpose: To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears. Methods: We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-co...

Full description

Saved in:
Bibliographic Details
Main Authors: Ali Makateb, Mahdi Soleymanzadeh, Saeed Soleiman-Meigooni, Ali Asgari, Mohammad Reza Etemadi, Amir Reza Mafi, Nader Mohammadi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-08-01
Series:Journal of Current Ophthalmology
Subjects:
Online Access:https://journals.lww.com/10.4103/joco.joco_251_23
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850210294030139392
author Ali Makateb
Mahdi Soleymanzadeh
Saeed Soleiman-Meigooni
Ali Asgari
Mohammad Reza Etemadi
Amir Reza Mafi
Nader Mohammadi
author_facet Ali Makateb
Mahdi Soleymanzadeh
Saeed Soleiman-Meigooni
Ali Asgari
Mohammad Reza Etemadi
Amir Reza Mafi
Nader Mohammadi
author_sort Ali Makateb
collection DOAJ
description Purpose: To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears. Methods: We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023. Patients were randomized into 3 groups: artificial tears (control), PVP-I 1%, and PVP-I 0.6% eye drops, 4 times daily for 5 days. Clinical signs at presentation and at 6 follow-up visits during the 1st 3 weeks of the acute phase were recorded. Patients were also followed up at 1 and 3 months. Results: Ninety-four patients completed the study, of which 30, 31, and 33 were in the control, PVP-I 1%, and PVP-I 0.6% groups, respectively. The mean age of the patients was 37.2 years (interquartile range: 25-46). The PCR result was positive in 75.6% of patients with the clinical suspicion. PVP-I, regardless of the concentration, was superior to the artificial tears in terms of time to resolution of lid swelling, discharge, and incidence of subsequent subepithelial infiltrates (P < 0.05). However, a concentration of 0.6% was equivalent to 1%. No significant adverse events were reported in any group. Conclusions: The PVP-I 0.6% topical drops are safe and well tolerated in patients with acute adenoviral keratoconjunctivitis. It can be substituted for the 1% solution as it has comparable effects in improving the clinical course and reducing subsequent complications.
format Article
id doaj-art-6e163b99de71482aa3060966d64337c8
institution OA Journals
issn 2452-2325
language English
publishDate 2024-08-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Current Ophthalmology
spelling doaj-art-6e163b99de71482aa3060966d64337c82025-08-20T02:09:48ZengWolters Kluwer Medknow PublicationsJournal of Current Ophthalmology2452-23252024-08-0135433734410.4103/joco.joco_251_23Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical TrialAli MakatebMahdi SoleymanzadehSaeed Soleiman-MeigooniAli AsgariMohammad Reza EtemadiAmir Reza MafiNader MohammadiPurpose: To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears. Methods: We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023. Patients were randomized into 3 groups: artificial tears (control), PVP-I 1%, and PVP-I 0.6% eye drops, 4 times daily for 5 days. Clinical signs at presentation and at 6 follow-up visits during the 1st 3 weeks of the acute phase were recorded. Patients were also followed up at 1 and 3 months. Results: Ninety-four patients completed the study, of which 30, 31, and 33 were in the control, PVP-I 1%, and PVP-I 0.6% groups, respectively. The mean age of the patients was 37.2 years (interquartile range: 25-46). The PCR result was positive in 75.6% of patients with the clinical suspicion. PVP-I, regardless of the concentration, was superior to the artificial tears in terms of time to resolution of lid swelling, discharge, and incidence of subsequent subepithelial infiltrates (P < 0.05). However, a concentration of 0.6% was equivalent to 1%. No significant adverse events were reported in any group. Conclusions: The PVP-I 0.6% topical drops are safe and well tolerated in patients with acute adenoviral keratoconjunctivitis. It can be substituted for the 1% solution as it has comparable effects in improving the clinical course and reducing subsequent complications.https://journals.lww.com/10.4103/joco.joco_251_23antiviral agentsepidemic keratoconjunctivitishuman adenoviruspovidone-iodinesubepithelial infiltrates
spellingShingle Ali Makateb
Mahdi Soleymanzadeh
Saeed Soleiman-Meigooni
Ali Asgari
Mohammad Reza Etemadi
Amir Reza Mafi
Nader Mohammadi
Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
Journal of Current Ophthalmology
antiviral agents
epidemic keratoconjunctivitis
human adenovirus
povidone-iodine
subepithelial infiltrates
title Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
title_full Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
title_fullStr Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
title_full_unstemmed Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
title_short Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial
title_sort comparison between the efficacy and tolerability of polyvinylpyrrolidone iodine eye drops 0 6 and 1 in adenoviral keratoconjunctivitis a randomized clinical trial
topic antiviral agents
epidemic keratoconjunctivitis
human adenovirus
povidone-iodine
subepithelial infiltrates
url https://journals.lww.com/10.4103/joco.joco_251_23
work_keys_str_mv AT alimakateb comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT mahdisoleymanzadeh comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT saeedsoleimanmeigooni comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT aliasgari comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT mohammadrezaetemadi comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT amirrezamafi comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial
AT nadermohammadi comparisonbetweentheefficacyandtolerabilityofpolyvinylpyrrolidoneiodineeyedrops06and1inadenoviralkeratoconjunctivitisarandomizedclinicaltrial